ArticleInternational journal of endocrinology2026
Research on a Predictive Model for Microalbuminuria in Type 2 Diabetes Based on Machine Learning and SHAP Analysis.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is associated with kidney damage, with microalbuminuria (MAU) serving as an early marker indicating the risk of progression to severe renal and cardiovascular complications, and there is an urgent need for effective prediction tools to identify MAU risk in T2DM patients and prevent adverse outcomes. This study aims to develop a machine learning-based model to enhance the early identification of high-risk individuals and facilitate timely, personalized interventions. Methods: The electronic medical records of 4170 patients were retrospectively extracted from the diabetes special database of Nanjing Drum Tower Hospital (Ethics approval number: 2021-403-02). The data were divided into training and testing sets (8:2 ratio), and random forest-based recursive feature elimination method was employed to identify the most pertinent input variables for the predictive model. Five machine learning models were applied to predict the progression to MAU. The Shapley additive explanations (SHAP) values were applied for model interpretation to assess feature contributions. Ten features were selected for the construction of a prediction model. Results: For predicting the progression to MAU, the Light GBM model demonstrated the best performance (AUC 0.85, 95% CI 0.82-0.88). By analyzing the Shapley values of the model outputs, we identified the key risk factors for predicting the diagnosis of MAU at both the cohort and individual levels. Conclusions: This study developed an interpretable machine learning model to predict MAU in T2DM patients, enabling effective risk stratification and identification of high-risk individuals based on baseline data to guide personalized clinical interventions and optimization of treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.